Denali Therapeutics Inc.

53.61+3.31+6.58%Vol 202.62K1Y Perf 177.78%
Apr 13th, 2021 15:38 DELAYED
BID53.49 ASK53.61
Open50.50 Previous Close50.30
Pre-Market- After-Market-
 - -%  - -
Target Price
87.14 
Analyst Rating
Strong Buy 1.54
Potential %
62.76 
Finscreener Ranking
★★★★★     64.35
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     59.74
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     86.19
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap6.49B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
46.58 
Earnings Date
6th May 2021

Today's Price Range

50.4953.75

52W Range

18.4593.94

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-7.74%
1 Month
-21.86%
3 Months
-33.66%
6 Months
14.29%
1 Year
177.78%
3 Years
163.28%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
DNLI53.613.31006.58
AAPL134.473.23002.46
GOOG2 272.9318.14000.80
MSFT258.352.44000.95
XOM55.730.23000.41
WFC39.82-0.9500-2.33
JNJ159.57-2.0700-1.28
FB311.01-0.5300-0.17
GE13.50-0.0900-0.66
JPM154.56-1.3900-0.89
Financial StrengthValueIndustryS&P 500US Markets
20.60
20.90
0.05
0.06
-
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-1 016.80
-980.80
-
40.41
RevenueValueIndustryS&P 500US Markets
332.06M
2.74
458.75
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.551.91447.27
Q03 20203.57-0.54-115.13
Q02 2020-0.61-0.568.20
Q01 2020-0.57-0.553.51
Q04 2019-0.53-0.56-5.66
Q03 2019-0.53-0.489.43
Q02 2019-0.46-0.61-32.61
Q01 2019-0.37-0.41-10.81
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.3544.44Positive
6/2021 QR-0.4234.38Positive
12/2021 FY-1.4635.40Positive
12/2022 FY-2.1520.96Positive
Next Report Date6th May 2021
Estimated EPS Next Report-0.35
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume202.62K
Shares Outstanding120.98M
Trades Count4.02K
Dollar Volume39.54M
Avg. Volume595.61K
Avg. Weekly Volume333.05K
Avg. Monthly Volume471.38K
Avg. Quarterly Volume556.86K

Denali Therapeutics Inc. (NASDAQ: DNLI) stock closed at 50.3 per share at the end of the most recent trading day (a -3.27% change compared to the prior day closing price) with a volume of 548.87K shares and market capitalization of 6.49B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 291 people. Denali Therapeutics Inc. CEO is Ryan J. Watts.

The one-year performance of Denali Therapeutics Inc. stock is 177.78%, while year-to-date (YTD) performance is -39.65%. DNLI stock has a five-year performance of %. Its 52-week range is between 18.45 and 93.94, which gives DNLI stock a 52-week price range ratio of 46.58%

Denali Therapeutics Inc. currently has a PE ratio of 84.10, a price-to-book (PB) ratio of 5.57, a price-to-sale (PS) ratio of 18.33, a price to cashflow ratio of 14.40, a PEG ratio of 2.32, a ROA of 6.45%, a ROC of -32.23% and a ROE of 9.00%. The company’s profit margin is 40.41%, its EBITDA margin is -980.80%, and its revenue ttm is $332.06 Million , which makes it $2.74 revenue per share.

Of the last four earnings reports from Denali Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.35 for the next earnings report. Denali Therapeutics Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Denali Therapeutics Inc. is Strong Buy (1.54), with a target price of $87.14, which is +62.76% compared to the current price. The earnings rating for Denali Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Denali Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Denali Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.56, ATR14 : 5.40, CCI20 : -123.64, Chaikin Money Flow : -0.14, MACD : -4.10, Money Flow Index : 32.52, ROC : -7.86, RSI : 38.00, STOCH (14,3) : 2.57, STOCH RSI : 0.10, UO : 28.15, Williams %R : -97.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Denali Therapeutics Inc. in the last 12-months were: Alexander O. Schuth (Option Excercise at a value of $0), Alexander O. Schuth (Sold 104 515 shares of value $7 419 993 ), Carole Ho (Option Excercise at a value of $279 344), Carole Ho (Sold 71 135 shares of value $3 226 586 ), David P. Schenkein (Sold 80 000 shares of value $5 905 312 ), Douglas Bratton (Sold 3 935 726 shares of value $112 668 990 ), Douglas K. Bratton (Sold 6 152 524 shares of value $256 760 862 ), Marc Tessier-Lavigne (Sold 950 000 shares of value $30 333 277 ), Ryan J. Watts (Option Excercise at a value of $0), Ryan J. Watts (Sold 157 921 shares of value $11 174 031 ), Steve E. Krognes (Option Excercise at a value of $0), Steve E. Krognes (Sold 154 483 shares of value $10 243 441 ), Vicki L. Sato (Sold 3 332 shares of value $196 633 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (66.67 %)
8 (66.67 %)
8 (72.73 %)
Moderate Buy
1 (8.33 %)
1 (8.33 %)
1 (9.09 %)
Hold
3 (25.00 %)
3 (25.00 %)
2 (18.18 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.54
Strong Buy
1.54
Strong Buy
1.41

Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

CEO: Ryan J. Watts

Telephone: +1 650 866-8548

Address: 161 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 291

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

52%48%

Bearish Bullish

59%41%

News

Stocktwits